Literature DB >> 34532085

Effectiveness of telerehabilitation on short-term quality of life of patients after esophageal cancer surgery during COVID-19: a single-center, randomized, controlled study.

Keqing Chen1, Fei Yao2, Xiaoyu Chen3, Yanjuan Lin4,5, Minqiang Kang1.   

Abstract

BACKGROUND: The occurrence of postoperative complications may lead to delayed recovery and a decline in physical function in the first 3 months after esophagectomy. The outbreak of COVID-19 imposed physical and emotional obstacles for traditional face-to-face rehabilitation. Meanwhile, the effectiveness of telerehabilitation remained unknown. In this study, we aimed to investigate the effectiveness of telerehabilitation.
METHODS: A cohort of 86 patients who received minimally invasive esophagectomy between September 2020 and January 2021 was randomly allocated into two groups. The telerehabilitation group received additional online consulting and training, including (I) precautions for nutritional support; (II) swallowing function training; (III) respiratory function training; (IV) guidance and feedback on matters such as patient's current vital signs, wound status, medication, and sleep status. The primary outcome was the change of quality of life (QOL) of each patient at 3 months after surgery.
RESULTS: No serious adverse events were observed in either group. The telerehabilitation group showed significant improvements in pain using the OLQ-C30 scale (P<0.001), and in choking using the QLQ-OES18 scale (P<0.001). The comparison of the QLQ-C30 and QES-18 score changes at three months after discharge revealed that nearly all aspects in the telerehabilitation group displayed more score changes with significant changes in the appetite loss and pain part (P<0.001 and P<0.05, respectively). The score changes in QLQ-OES18 revealed significant improvement in swallowing saliva (P<0.05), as well slight improvements in choking, dry mouth, taste, and cough without significance.
CONCLUSIONS: Our study demonstrated that telerehabilitation was at least an important supplement to traditional face-to-face consulting and training for patients after esophageal cancer surgery during the COVID-19 period. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100049186. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  COVID-19; Telerehabilitation; minimally invasive esophagectomy; quality of life (QOL)

Year:  2021        PMID: 34532085      PMCID: PMC8421896          DOI: 10.21037/jgo-21-385

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  22 in total

Review 1.  Meta-analysis of health-related quality of life after minimally invasive versus open oesophagectomy for oesophageal cancer.

Authors:  J H Kauppila; S Xie; A Johar; S R Markar; P Lagergren
Journal:  Br J Surg       Date:  2017-06-20       Impact factor: 6.939

2.  Physical decline and its implications in the management of oesophageal and gastric cancer: a systematic review.

Authors:  Linda O'Neill; Jonathan Moran; Emer M Guinan; John V Reynolds; Juliette Hussey
Journal:  J Cancer Surviv       Date:  2018-05-23       Impact factor: 4.442

3.  The pre- and postoperative course of functional status in patients undergoing esophageal cancer surgery.

Authors:  Maarten A van Egmond; Marike van der Schaaf; Jean H G Klinkenbijl; Jos W R Twisk; Raoul H H Engelbert; Mark I van Berge Henegouwen
Journal:  Eur J Surg Oncol       Date:  2019-08-06       Impact factor: 4.424

4.  Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.

Authors:  Jessie A Elliott; Suzanne L Doyle; Conor F Murphy; Sinead King; Emer M Guinan; Peter Beddy; Narayanasamy Ravi; John V Reynolds
Journal:  Ann Surg       Date:  2017-11       Impact factor: 12.969

Review 5.  Preoperative risk assessment and prevention of complications in patients with esophageal cancer.

Authors:  Brechtje A Grotenhuis; Bas P L Wijnhoven; Frank Grüne; Jasper van Bommel; Hugo W Tilanus; J Jan B van Lanschot
Journal:  J Surg Oncol       Date:  2010-03-01       Impact factor: 3.454

6.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

7.  An analysis of the factors contributing to a reduction in the incidence of pulmonary complications following an esophagectomy for esophageal cancer.

Authors:  Masaki Nakamura; Makoto Iwahashi; Mikihito Nakamori; Koichiro Ishida; Teiji Naka; Takeshi Iida; Masahiro Katsuda; Toshiaki Tsuji; Yoshihiro Nakatani; Hiroki Yamaue
Journal:  Langenbecks Arch Surg       Date:  2007-12-11       Impact factor: 3.445

8.  Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer.

Authors:  J M Blazeby; T Conroy; E Hammerlid; P Fayers; O Sezer; M Koller; J Arraras; A Bottomley; C W Vickery; P L Etienne; D Alderson
Journal:  Eur J Cancer       Date:  2003-07       Impact factor: 9.162

9.  Effect of preoperative inspiratory muscle training on physical functioning following esophagectomy.

Authors:  E M Guinan; C Forde; L O'Neill; J Gannon; S L Doyle; K Valkenet; J C A Trappenburg; R van Hillegersberg; N Ravi; J M Hussey; J V Reynolds
Journal:  Dis Esophagus       Date:  2019-02-01       Impact factor: 3.429

10.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

View more
  1 in total

1.  Mental Health in Postoperative Thyroid Patients During the COVID-19 Pandemic.

Authors:  Shijie Yang; Xiequn Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-28       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.